In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Prevention and mitigation of LV dysfunction

Profs. Anita Arnold, Florida State University, USA and Peter Van Der Meer, University Medical Center Groningen, The Netherlands, discuss the prevention and mitigation of LV dysfunction in patients receiving cardiotoxic cancer therapy.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.